VANCOUVER, Sept. 4, 2012 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO), today announced it will be presenting at the Rodman & Renshaw 2012 Annual Global Investment Conference in New York City.
Management will deliver the Company presentation to conference attendees on Tuesday, September 11 at 1:35 PM ET in the North Foyer at the Waldorf Astoria Hotel.
Andrew Rae, President & CEO of iCo, commented that, "This conference provides us with the opportunity to highlight our clinical pipeline and specifically our lead candidate iCo-007 in the iDEAL study for Diabetic Macular Edema, from which we expect to announce interim data before the end of the year."
More than 300 public and private companies from around the world are registered to present in front of an audience of over 3,000 attendees. Newt Gingrich, 58th Speaker of the U.S. House of Representatives, will open the Conference as the Keynote Speaker on Monday, September 10.
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME); iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011. iCo trades on the TSX Venture Exchange under the symbol "ICO". For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings; actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: iCo Therapeutics Inc.
Mr. John Meekison, CFO
604-602-9414 x 224
Michael Moore, Investor Relations
David Waldman/Klea Theoharis